SECsense Logo

Marker Therapeutics, Inc. 8-K Report: December 2024 Insights & Updates

$MRKR
Form 8-K
Filed on: 2024-12-17
Source
Marker Therapeutics, Inc. 8-K Report: December 2024 Insights & Updates

Based on the provided XML section of the financial report, here are the key pieces of information and insights:

  1. Company Information:
  • Name: Marker Therapeutics, Inc.
  • CIK: 0001094038
  • Type of filing: 8-K (Current Report)
  • Ticker Symbol: MRKR
  • Exchange: NASDAQ
  • Par Value of Common Stock: $0.001 per share
  • Address: 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, TX 77021
  • Phone Number: 713 400-6400
  1. Filing Date:
  • Filing Date: December 17, 2024
  1. Financial Metrics:
  • The report indicates a context marked as "AsOf2024-12-17", suggesting that the data pertains to a specific date (December 17, 2024).
  • The unit of measure for financial figures is indicated as USD (U.S. Dollars) and shares for stock metrics.
  1. Contextual Details:
  • The filing utilizes various XML namespaces typical in XBRL filings, indicating it is structured for machine-readable reporting.
  • The schema reference points to an XSD file named "mrkr-20241217.xsd", which likely defines the structure of the data contained within the filing.

Insights:

  • The use of the 8-K filing indicates that Marker Therapeutics may have had a significant event or development that needed to be reported to the SEC, which can include mergers, acquisitions, financial results, or other important company news.
  • The detailed contact information and the structured format suggest that the company is compliant with SEC regulations for public disclosures.
  • The par value of the common stock is relatively low, which is common for many biotechnology companies, reflecting their growth stage and potential for future capital raises.

This information indicates that Marker Therapeutics, Inc. is actively engaged in regulatory compliance and may have important updates relevant to its shareholders and potential investors as of the specified date. Further analysis of this 8-K in the context of other filings and market conditions would provide additional insights into the company's current standing and future outlook.